← 產業報告目錄

Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-11-21頁數 367報告編號 BT5576

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The PDX model market is expected to reach USD 0.66 billion in 2030 from USD 0.37 billion in 2025, at a CAGR of 12.5% during the forecast period. The market is primarily driven by the increasing incidence of cancer and the growing demand for effective preclinical models that closely replicate human tumor biology. The increasing use of patient-derived xenograft (PDX) models in oncology research to evaluate drug efficacy, discover biomarkers, and inform personalized treatment approaches further supports market growth. Additionally, advancements in immunodeficient mouse models and the integration of PDX platforms with next-generation sequencing technologies are enhancing their translational value. However, the high cost and time-intensive nature of PDX model development, along with ethical considerations and variability in model reproducibility, continue to restrain widespread market adoption. “Orthotopic implantation segment is expected to grow at the highest CAGR during the forecast period” The orthotopic implantation segment is expected to grow at the highest CAGR in the patient-derived xenograft (PDX) model market owing to its superior ability to mimic the natural tumor environment and disease progression seen in human cancers. This technique allows tumor cells to be implanted at their original tissue site, enabling a more accurate representation of tumor-stroma interactions, angiogenesis, and metastatic spread. As a result, orthotopic models provide higher translational relevance and predictive accuracy for assessing drug efficacy and resistance mechanisms compared to other model types. The increasing adoption of targeted therapies and immunotherapies has further fueled the demand for orthotopic models, as they provide a more physiologically relevant context for evaluating therapeutic responses. Additionally, advancements in imaging modalities and microsurgical techniques have improved the reproducibility and monitoring of orthotopic PDX studies, making them more accessible and reliable for preclinical research. These advantages collectively drive the rapid growth of the orthotopic implantation segment in the global PDX model market. “Gastrointestinal tumor model segment holds the largest share of the market” The gastrointestinal (GI) tumor model segment holds the largest share of the patient-derived xenograft (PDX) model market, driven by the high global incidence of gastrointestinal malignancies, including colorectal, gastric, pancreatic, and liver cancers. These cancers are among the leading causes of cancer-related mortality, creating a strong demand for reliable preclinical models that accurately replicate tumor heterogeneity and progression. Gastrointestinal PDX models closely preserve the histological and genetic characteristics of patient tumors, enabling more predictive evaluation of therapeutic efficacy and resistance mechanisms. Their robust application in assessing targeted therapies, immunotherapies, and combination treatment strategies has made them a cornerstone of translational oncology research. Furthermore, the growing emphasis on precision medicine and the rising volume of clinical trials focused on GI cancers have accelerated the adoption of these models. Continuous advancements in engraftment techniques and molecular profiling further enhance the utility of gastrointestinal PDX models, solidifying their leading position in the global market. “The US is expected to grow at the highest CAGR during the forecast period” The US is expected to register the highest growth rate in the patient-derived xenograft (PDX) model market during the forecast period. This growth is primarily driven by the strong presence of leading pharmaceutical and biotechnology companies, well-established research infrastructure, and extensive oncology research initiatives. The rising prevalence of cancer, coupled with increasing adoption of personalized medicine and targeted therapy development, is significantly boosting the demand for PDX models. Furthermore, growing investment in translational and preclinical cancer research, along with strong collaborations between academic institutions and industry players, is accelerating market expansion. Additionally, the availability of advanced laboratory facilities, the presence of comprehensive biobanking systems, and supportive government funding for cancer drug discovery further strengthen the country’s position in the global market. The US regulatory environment also promotes innovation while ensuring the reliability and ethical compliance of PDX-based studies. These factors collectively contribute to the rapid adoption of PDX models, reinforcing North America’s leadership in the global market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5% JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv (US), Pharmatest Services (Finland), Hera Biolabs (US), EPO Berlin-Buch GmbH (Germany), XenTech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (Taiwan), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (China), Creative Animodel (US), BioDuro (US), Aragen Life Sciences (India), LIDE Shanghai Biotech, Ltd (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co., Ltd. (China), and Shanghai ChemPartner (China) are some of the key companies offering PDX models. Research Coverage This research report categorizes the PDX model market by implantation method (subcutaneous implantation, orthotopic implantation, others), type (mouse model, rat model), tumor type (gastrointestinal, gynecological, respiratory, urological, hematological, other tumor models), application (preclinical drug development, biomarker analysis, translational research, biobanks), end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the PDX model market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the PDX model market. This report also includes a competitive analysis of emerging startups in the PDX model industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX models, rising investments in cancer research), restraints (discontinuation of animal models for clinical trials by the FDA), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the PDX model market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the PDX model market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including JSR Corporation (Japan), WuXi AppTec (China), The Jackson Laboratory (US), Charles River Laboratories (US), Taconic Biosciences, Inc. (US), among others offering products for the PDX model market. Other companies include BioDuro (US), Aragen Life Sciences (India), LIDE Shanghai Biotech, Ltd (China), Certis Oncology Solutions (US), InnoSer (Netherlands), among others, in the PDX model market
目錄 Table of Contents
1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.2.1 MARKET SEGMENTATION & REGIONAL SCOPE 36 1.2.2 YEARS CONSIDERED 37 1.3 STUDY SCOPE 37 1.3.1 INCLUSIONS & EXCLUSIONS 37 1.3.2 CURRENCY CONSIDERED 38 1.4 STAKEHOLDERS 38 1.5 SUMMARY OF CHANGES 39 2 EXECUTIVE SUMMARY 40 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 40 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC IMPERATIVES 43 2.3 DISRUPTIVE TRENDS SHAPING PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 44 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 44 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 45 3 PREMIUM INSIGHTS 46 3.1 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE AND COUNTRY (2024) 46 3.2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47 3.3 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE, BY IMPLANTATION, 2025 VS. 2030 (%) 47 3.4 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE, BY SERVICE, 2024 (%) 48 4 MARKET OVERVIEW 49 4.1 INTRODUCTION 49 4.2 MARKET DYNAMICS 49 4.2.1 DRIVERS 50 4.2.1.1 Growing demand for immuno-oncology and complex biologics 50 4.2.1.2 Rising preference for humanized PDX models 50 4.2.1.3 Focus on government-funded initiatives for cancer research 50 4.2.2 RESTRAINTS 51 4.2.2.1 Introduction of 3D printed models 51 4.2.2.2 Ethical concerns and regulatory restrictions 52 4.2.3 OPPORTUNITIES 53 4.2.3.1 Increasing preference for personalized medicines in oncology 53 4.2.3.2 Growing demand for CDX models for PDX model vendors 53 4.2.4 CHALLENGES 54 4.2.4.1 Limitations of humanized mouse models 54 4.3 UNMET NEEDS & WHITE SPACES 55 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 55 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 55 5 INDUSTRY TRENDS 56 5.1 PORTER’S FIVE FORCES ANALYSIS 56 5.1.1 THREAT OF NEW ENTRANTS 57 5.1.2 THREAT OF SUBSTITUTES 57 5.1.3 BARGAINING POWER OF BUYERS 57 5.1.4 BARGAINING POWER OF SUPPLIERS 57 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 58 5.2 ECOSYSTEM ANALYSIS 58 5.3 VALUE CHAIN ANALYSIS 58 5.4 PRICING ANALYSIS 60 5.4.1 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY KEY PLAYER, 2022−2024 60 5.4.2 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024 61 5.4.3 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024 62 5.4.4 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY REGION, 2024 62 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63 5.6 PATENT ANALYSIS 64 5.6.1 METHODOLOGY 64 5.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 64 5.6.3 LIST OF KEY PATENTS 66 5.7 TRADE DATA ANALYSIS 66 5.7.1 IMPORT DATA FOR HS CODE 106.19.90, 2020–2024 67 5.7.2 EXPORT DATA FOR HS CODE 106.19.90, 2020–2024 68 5.8 IMPACT OF 2025 US TARIFF ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 68 5.8.1 KEY TARIFF RATES 69 5.8.2 PRICE IMPACT ANALYSIS 70 5.8.3 KEY IMPACT ON VARIOUS REGIONS 70 5.8.3.1 North America 70 5.8.3.2 Europe 71 5.8.3.3 Asia Pacific 71 5.8.3.4 Rest of the World 71 5.8.4 IMPACT ON END-USE INDUSTRIES 71 5.8.4.1 Pharmaceutical & biotechnology companies 72 5.8.4.2 CROs & CDMOs 72 5.8.4.3 Academic & research institutes 72 5.9 MACROECONOMIC OUTLOOK 73 5.9.1 INTRODUCTION 73 5.9.2 GDP TRENDS AND FORECAST 73 5.9.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 73 5.9.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 74 5.10 KEY CONFERENCES & EVENTS, 2025–2026 74 5.11 INVESTMENT & FUNDING SCENARIO 75 5.11.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 76 5.12 CASE STUDY ANALYSIS 76 5.12.1 IMAGING-READY ORTHOTOPIC PDX FOR PEDIATRIC BRAIN TUMORS 76 5.12.2 HOST-STRAIN SELECTION USING BREAST CANCER PDX 77 5.12.3 RESISTANCE-ANCHORED PDX PANEL TO DESIGN MOUSE CLINICAL TRIAL 77 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78 6.1 KEY EMERGING TECHNOLOGIES 78 6.1.1 NEXT-GENERATION SEQUENCING 78 6.1.2 GENE EDITING 78 6.2 COMPLEMENTARY TECHNOLOGIES 78 6.2.1 MULTI-OMICS 78 6.2.2 MULTI-MODEL PRECLINICAL IMAGING 79 6.3 TECHNOLOGY ROADMAP 79 6.4 FUTURE APPLICATIONS 79 6.5 IMPACT OF AI/GEN AI ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 80 6.5.1 TOP USE CASES & MARKET POTENTIAL 80 6.5.2 CASE STUDIES OF AI IMPLEMENTATION 81 6.5.3 BEST PRACTICES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS CREATION 81 6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 82 6.5.5 HIGH READINESS VS. ADOPTION BARRIERS 83 7 SUSTAINABILITY AND REGULATORY LANDSCAPE 84 7.1 REGIONAL REGULATIONS & COMPLIANCE 84 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 7.1.2 INDUSTRY STANDARDS 86 7.1.2.1 North America 86 7.1.2.2 Europe 88 7.1.2.3 Asia Pacific 89 7.1.2.4 Latin America 91   7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 91 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 92 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 94 8.1 DECISION-MAKING PROCESS 94 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 95 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 96 8.4 UNMET NEEDS FROM END-USE INDUSTRIES 96 9 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE 98 9.1 INTRODUCTION 99 9.2 PDX MODELS 99 9.2.1 MOUSE MODEL 102 9.2.1.1 Proven efficacy of mouse model in cancer research and drug development to boost segment growth 102 9.2.2 RAT MODEL 105 9.2.2.1 Emergence of advanced technologies in PDX rat models to aid market growth 105 9.3 SERVICES 108 9.3.1 MODEL CREATION & EXPANISON SERVICES 111 9.3.1.1 Need for faster passaging of models to to build study-ready cohorts (P1–P3) to boost segment growth 111 9.3.2 MODEL CHARACTERIZATION SERVICES 114 9.3.2.1 Growing demand for biomarker analysis to drive segment growth 114 9.3.3 CRYOPRESERVATION SERVICES 117 9.3.3.1 Reliable and low-passage biobanking services to offer growth opportunities 117 9.3.4 OTHER PDX SERVICES 120 10 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD 123 10.1 INTRODUCTION 124 10.2 SUBCUTANEOUS IMPLANTATION 124 10.2.1 STANDARDIZED AND SCALABLE PDX MODEL EXPANSION TO DRIVE SEGMENT GROWTH 124 10.3 ORTHOTOPIC IMPLANTATION 127 10.3.1 DEMAND FOR CLINICALLY RELEVANT AND SITE-SPECIFIC PDX MODELS TO BOOST SEGMENT GROWTH 127 10.4 OTHER IMPLANTATION METHODS 131   11 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE 136 11.1 INTRODUCTION 137 11.2 GASTROINTESTINAL TUMOR MODEL 137 11.2.1 HIGH TISSUE AVAILABILITY AND STANDARDIZED ENGRAFTMENT PROTOCOLS TO FUEL MARKET GROWTH 137 11.3 GYNECOLOGICAL TUMOR MODEL 141 11.3.1 EXPANDING ORTHOTOPIC AND HUMANIZED PDX APPLICATIONS TO DRIVE MARKET 141 11.4 RESPIRATORY TUMOR MODEL 144 11.4.1 INCREASING ADOPTION OF ORTHOTOPIC AND HUMANIZED MODELS TO BOOST SEGMENT GROWTH 144 11.5 UROLOGICAL TUMOR MODEL 147 11.5.1 EXPANSION OF HORMONE-CONTEXT AND IMMUNE-COMPETENT MODELS TO FAVOR MARKET ADOPTION 147 11.6 HEMATOLOGICAL TUMOR MODEL 150 11.6.1 RISING ADOPTION OF HUMANIZED AND RELAPSE-DERIVED MODELS TO DRIVE SEGMENT GROWTH 150 11.7 OTHER TUMOR MODELS 153 12 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION 157 12.1 INTRODUCTION 158 12.2 PRECLINICAL RESEARCH 158 12.2.1 HIGH IMPORTANCE FOR PDX IN EFFICACY CONFIRMATION TO DRIVE MARKET 158 12.3 BIOMARKER ANALYSIS 161 12.3.1 DEMAND FOR MULTI-OMICS TO AUGMENT MARKET GROWTH 161 12.4 TRANSLATIONAL RESEARCH 164 12.4.1 DEMAND FOR PDX MODELS IN CO-CLINICAL TRIAL DESIGNS TO BOOST SEGMENT GROWTH 164 12.5 BIOBANKING 167 12.5.1 DEMAND FOR PDX MODELS IN SPECIALIZED BANKS TO SPUR MARKET GROWTH 167 13 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER 171 13.1 INTRODUCTION 172 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172 13.2.1 INTEGRATION OF TRANSLATIONALLY RELEVANT PDX WORKFLOWS TO DRIVE MARKET GROWTH 172 13.3 CROS & CDMOS 176 13.3.1 EXPANDED OUTSOURCING THROUGH INTEGRATED WORKFLOWS TO FUEL MARKET GROWTH 176 13.4 ACADEMIC & RESEARCH INSTITUTES 179 13.4.1 ENHANCED INSTITUTIONAL BIOBANKS AND MULTI-OMIC PROFILING TO AUGMENT MARKET GROWTH 179   14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION 182 14.1 INTRODUCTION 183 14.2 NORTH AMERICA 183 14.2.1 US 187 14.2.1.1 US to dominate North American PDX models market during study period 187 14.2.2 CANADA 190 14.2.2.1 Growth research and academic activities on oncology to fuel market growth 190 14.3 EUROPE 193 14.3.1 GERMANY 197 14.3.1.1 Growth in biotechnology industry and strong pharma presence to spur market growth 197 14.3.2 UK 200 14.3.2.1 Increasing focus on cancer research to propel market 200 14.3.3 FRANCE 203 14.3.3.1 Robust research activities in immune-oncology to drive market growth 203 14.3.4 ITALY 206 14.3.4.1 Growing pharmaceutical & biotechnology industry and increasing focus on radiopharmaceuticals to favor market growth 206 14.3.5 SPAIN 209 14.3.5.1 Increasing translational activities to boost market growth 209 14.3.6 REST OF EUROPE 212 14.4 ASIA PACIFIC 215 14.4.1 CHINA 219 14.4.1.1 Favorable investments in life sciences research to drive market 219 14.4.2 JAPAN 222 14.4.2.1 Increasing focus on personalized diagnostics products to drive market 222 14.4.3 INDIA 225 14.4.3.1 Favorable initiatives for drug discovery & development to boost market growth 225 14.4.4 AUSTRALIA 228 14.4.4.1 High number of research institutes to favor market growth 228 14.4.5 SOUTH KOREA 231 14.4.5.1 Innovation in health and biotech sectors to support market uptake 231 14.4.6 REST OF ASIA PACIFIC 234 14.5 LATIN AMERICA 237 14.5.1 BRAZIL 240 14.5.1.1 Increasing investments in biopharmaceutical research to fuel uptake 240 14.5.2 MEXICO 243 14.5.2.1 Expanding healthcare ecosystem to support market growth 243 14.5.3 REST OF LATIN AMERICA 246 14.6 MIDDLE EAST 249 14.6.1 GCC COUNTRIES 252 14.6.1.1 Kingdom of Saudi Arabia 255 14.6.1.1.1 Advanced healthcare sector and prevalence of chronic diseases to boost market 255 14.6.1.2 UAE 258 14.6.1.2.1 Increasing R&D activities and growing demand for personalized medicines to propel market 258 14.6.1.3 Rest of GCC Countries 261 14.6.2 REST OF MIDDLE EAST 264 14.7 AFRICA 267 14.7.1 INCREASING FOCUS ON PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH 267 15 COMPETITIVE LANDSCAPE 271 15.1 INTRODUCTION 271 15.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 271 15.2.1 STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2025 271 15.3 REVENUE ANALYSIS, 2022–2024 273 15.4 MARKET SHARE ANALYSIS, 2024 273 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 276 15.5.1 STARS 276 15.5.2 EMERGING LEADERS 276 15.5.3 PERVASIVE PLAYERS 276 15.5.4 PARTICIPANTS 276 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 278 15.5.5.1 Company footprint 278 15.5.5.2 Region footprint 279 15.5.5.3 Model type & service footprint 280 15.5.5.4 Tumor type footprint 281 15.5.5.5 Implantation method footprint 282 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 283 15.6.1 PROGRESSIVE COMPANIES 283 15.6.2 RESPONSIVE COMPANIES 283 15.6.3 DYNAMIC COMPANIES 283 15.6.4 STARTING BLOCKS 283 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SME PLAYERS, 2024 285 15.6.5.1 Detailed list of key startups/SMEs 285 15.6.5.2 Competitive benchmarking of key startups/SMEs 286   15.7 COMPANY VALUATION & FINANCIAL METRICS 286 15.7.1 FINANCIAL METRICS 286 15.7.2 COMPANY VALUATION 287 15.8 BRAND/PRODUCT COMPARISON 288 15.9 COMPETITIVE SCENARIO 289 15.9.1 DEALS 289 15.9.2 EXPANSIONS 290 16 COMPANY PROFILES 291 16.1 KEY PLAYERS 291 16.1.1 CHARLES RIVER LABORATORIES 291 16.1.1.1 Business overview 291 16.1.1.2 Products/Services offered 292 16.1.1.3 Recent developments 294 16.1.1.3.1 Deals 294 16.1.1.3.2 Expansions 295 16.1.1.4 MnM view 295 16.1.1.4.1 Key strengths 295 16.1.1.4.2 Strategic choices 296 16.1.1.4.3 Weaknesses & competitive threats 296 16.1.2 THE JACKSON LABORATORY 297 16.1.2.1 Business overview 297 16.1.2.2 Products/Services offered 298 16.1.2.3 Recent developments 299 16.1.2.3.1 Deals 299 16.1.2.3.2 Expansions 300 16.1.2.4 MnM view 300 16.1.2.4.1 Key strengths 300 16.1.2.4.2 Strategic choices 300 16.1.2.4.3 Weaknesses & competitive threats 301 16.1.3 INOTIV 302 16.1.3.1 Business overview 302 16.1.3.2 Products/Services offered 303 16.1.3.3 Recent developments 305 16.1.3.3.1 Expansions 305 16.1.3.4 MnM view 305 16.1.3.4.1 Key strengths 305 16.1.3.4.2 Strategic choices 305 16.1.3.4.3 Weaknesses & competitive threats 306   16.1.4 JSR CORPORATION 307 16.1.4.1 Business overview 307 16.1.4.2 Product/Services offered 308 16.1.4.3 Recent developments 309 16.1.4.3.1 Deals 309 16.1.4.3.2 Expansions 310 16.1.4.4 MnM view 310 16.1.4.4.1 Key strengths 310 16.1.4.4.2 Strategic choices 310 16.1.4.4.3 Weaknesses & competitive threats 310 16.1.5 GENOWAY 311 16.1.5.1 Business overview 311 16.1.5.2 Product/Solutions offered 312 16.1.5.3 MnM view 312 16.1.5.3.1 Key strengths 312 16.1.5.3.2 Strategic choices 312 16.1.5.3.3 Weaknesses & competitive threats 313 16.1.6 WUXI APPTEC + WUXI BIOLOGICS 314 16.1.6.1 Business overview 314 16.1.6.2 Product/Services offered 315 16.1.6.3 Recent developments 316 16.1.6.3.1 Deals 316 16.1.6.3.2 Expansions 318 16.1.7 BIOCYTOGEN PHARMACEUTICALS CO., LTD. 319 16.1.7.1 Business overview 319 16.1.7.2 Product/Services offered 320 16.1.7.3 Recent developments 321 16.1.7.3.1 Product/Service upgrades 321 16.1.7.3.2 Expansions 321 16.1.8 TACONIC BIOSCIENCES, INC. 323 16.1.8.1 Business overview 323 16.1.8.2 Products/Services offered 323 16.1.8.3 Recent developments 324 16.1.8.3.1 Product/Service launches 324 16.1.8.3.2 Deals 325 16.1.8.3.3 Expansions 325 16.1.9 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE) 326 16.1.9.1 Business overview 326 16.1.9.2 Products/Services offered 326   16.1.10 CHAMPIONS ONCOLOGY, INC. 328 16.1.10.1 Business overview 328 16.1.10.2 Products/Services offered 329 16.1.10.3 Recent developments 329 16.1.10.3.1 Deals 329 16.1.11 PHARMARON 330 16.1.11.1 Business overview 330 16.1.11.2 Products/Services offered 331 16.1.12 SYNGENE INTERNATIONAL LIMITED 333 16.1.12.1 Business overview 333 16.1.12.2 Products/Services offered 334 16.1.13 LABCORP 335 16.1.13.1 Business overview 335 16.1.13.2 Products/Services offered 336 16.1.14 EUROFINS SCIENTIFIC 337 16.1.14.1 Business overview 337 16.1.14.2 Products/Services offered 338 16.1.15 VITALSTAR BIOTECHNOLOGY CO., LTD. 339 16.1.15.1 Business overview 339 16.1.15.2 Products/Services offered 339 16.2 OTHER PLAYERS 340 16.2.1 CREATIVE ANIMODEL 340 16.2.2 JOINN LABORATORIES (CHINA) CO., LTD. 341 16.2.3 CREATIVE BIOLABS 342 16.2.4 ARAGEN LIFE SCIENCES LTD. 343 16.2.5 PHARMTEST SERVICES 344 16.2.6 LIDE SHANGHAI BIOTECH CO., LTD. 345 16.2.7 CERTIS ONCOLOGY SOLUTIONS 345 16.2.8 INNOSER 346 16.2.9 SHANGHAI CHEMPARTNER 346 16.2.10 IVRS AB 347 17 RESEARCH METHODOLOGY 348 17.1 RESEARCH DATA 348 17.1.1 SECONDARY DATA 349 17.1.2 KEY OBJECTIVES OF SECONDARY RESEARCH 349 17.1.3 PRIMARY DATA 349 17.2 MARKET ESTIMATION METHODOLOGY 350 17.2.1 COMPANY REVENUE ANALYSIS: BOTTOM-UP APPROACH 351 17.2.2 INSIGHTS FROM PRIMARY EXPERTS 353 17.2.3 TOP-DOWN APPROACH 353   17.3 GROWTH FORECAST 355 17.4 DATA TRIANGULATION 356 17.5 STUDY ASSUMPTIONS 357 17.6 RESEARCH LIMITATIONS 357 17.7 MARKET FORECAST 358 17.8 RISK ANALYSIS 358 18 APPENDIX 359 18.1 DISCUSSION GUIDE 359 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363 18.3 CUSTOMIZATION OPTIONS 365 18.4 RELATED REPORTS 365 18.5 AUTHOR DETAILS 366
圖表清單 List of Tables & Figures
TABLE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: INCLUSIONS & EXCLUSIONS 37 TABLE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPACT OF PORTER’S FIVE FORCES 57 TABLE 3 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY KEY PLAYER, 2022−2024 60 TABLE 4 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024 61 TABLE 5 AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024 62 TABLE 6 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024 62 TABLE 7 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 64 TABLE 8 LIST OF KEY PATENTS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2023–2025 66 TABLE 9 IMPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND) 67 TABLE 10 EXPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND) 68 TABLE 11 US-AJUSTED RECIPROCAL TARIFF RATES 69 TABLE 12 KEY PRODUCT-RELATED TARIFF: LIVE ANIMALS, PRODUCT OF ANIMAL ORIGIN, MISCELLANEOUS CHEMICAL PRODUCTS 70 TABLE 13 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 70 TABLE 14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 74 TABLE 15 INVESTMENT & FUNDING ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY KEY PLAYER, 2022−2025 75 TABLE 16 CASE STUDIES OF AI IMPLEMENTATION IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 81 TABLE 17 HIGH READINESS VS. ADOPTION BARRIERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 83 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 22 VENDOR CERTIFICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 92 TABLE 23 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 99 TABLE 24 PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 99 TABLE 25 PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 26 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 27 EUROPE: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 28 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 29 LATIN AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 30 MIDDLE EAST: PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 31 GCC COUNTRIES: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 32 MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 33 NORTH AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 34 EUROPE: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 35 ASIA PACIFIC: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 36 LATIN AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 37 MIDDLE EAST: MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 38 GCC COUNTRIES: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 39 RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 40 NORTH AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 41 EUROPE: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 42 ASIA PACIFIC: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 43 LATIN AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 44 MIDDLE EAST: RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 45 GCC COUNTRIES: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 46 PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 108 TABLE 47 PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 48 NORTH AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 49 EUROPE: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 50 ASIA PACIFIC: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 51 LATIN AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 52 MIDDLE EAST: PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 53 GCC COUNTRIES: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 54 MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 55 NORTH AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 56 EUROPE: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 57 ASIA PACIFIC: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 58 LATIN AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 59 MIDDLE EAST: MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 60 GCC COUNTRIES: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 61 MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 62 NORTH AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 63 EUROPE: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 64 ASIA PACIFIC: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 65 LATIN AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 66 MIDDLE EAST: MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 67 GCC COUNTRIES: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 68 CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 69 NORTH AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 70 EUROPE: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 71 ASIA PACIFIC: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 72 LATIN AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 73 MIDDLE EAST: CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 74 GCC COUNTRIES: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 75 OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 76 NORTH AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 77 EUROPE: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 78 ASIA PACIFIC: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 79 LATIN AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 80 MIDDLE EAST: OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 81 GCC COUNTRIES: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 82 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 124 TABLE 83 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 84 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 85 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 86 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 87 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 88 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 89 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 90 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 91 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 92 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 93 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 94 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 95 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 96 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 97 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 98 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 99 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 100 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 101 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 102 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 103 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 104 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 137 TABLE 105 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 106 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 107 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 108 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 109 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 110 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 111 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 112 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 113 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 114 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 115 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 116 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 117 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 118 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 119 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 120 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 121 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 122 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 123 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 124 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 125 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 126 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 128 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 129 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 130 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 131 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 132 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 133 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 134 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 135 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 136 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 137 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 138 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 139 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 140 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 141 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 143 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 144 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 145 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 146 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 147 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 158 TABLE 148 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 149 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 150 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 151 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 152 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 153 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 154 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 155 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 156 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 157 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 158 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 159 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 160 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 161 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 162 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 163 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 164 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 165 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 166 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 167 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 168 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 169 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 170 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 171 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 172 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 173 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 174 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 175 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 176 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 172 TABLE 177 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 178 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 179 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 181 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 182 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 183 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 184 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 185 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 186 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 187 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 188 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 189 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 190 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 191 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 192 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 193 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 194 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 195 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 196 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 197 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 198 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 199 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 200 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 185 TABLE 201 NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 202 NORTH AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 203 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 186 TABLE 204 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 186 TABLE 205 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187 TABLE 206 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 207 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 188 TABLE 208 US: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 209 US: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 210 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 189 TABLE 211 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 189 TABLE 212 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 213 US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 214 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 191 TABLE 215 CANADA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 216 CANADA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 217 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 192 TABLE 218 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 192 TABLE 219 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 220 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 193 TABLE 221 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 222 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 194 TABLE 223 EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 224 EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 225 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 195 TABLE 226 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 196 TABLE 227 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196 TABLE 228 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 197 TABLE 229 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 197 TABLE 230 GERMANY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 231 GERMANY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 232 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 198 TABLE 233 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 199 TABLE 234 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 199 TABLE 235 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 200 TABLE 236 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 200 TABLE 237 UK: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 238 UK: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 239 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 201 TABLE 240 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 202 TABLE 241 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 202 TABLE 242 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 243 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 203 TABLE 244 FRANCE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 245 FRANCE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 246 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 204 TABLE 247 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 205 TABLE 248 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 249 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 250 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 206 TABLE 251 ITALY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 207 TABLE 252 ITALY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 207 TABLE 253 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 207 TABLE 254 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 208 TABLE 255 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 256 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 257 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 209 TABLE 258 SPAIN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 259 SPAIN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 260 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 210 TABLE 261 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 211 TABLE 262 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 211 TABLE 263 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 212 TABLE 264 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 212 TABLE 265 REST OF EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 266 REST OF EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 267 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 213 TABLE 268 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 214 TABLE 269 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 214 TABLE 270 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 271 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 216 TABLE 272 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 273 ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 274 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 217 TABLE 275 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2023–2030 (USD MILLION) 218 TABLE 276 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 277 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 278 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 219 TABLE 279 CHINA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 280 CHINA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 281 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 220 TABLE 282 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 221 TABLE 283 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221 TABLE 284 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 285 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 222 TABLE 286 JAPAN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 287 JAPAN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 288 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 223 TABLE 289 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 224 TABLE 290 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 224 TABLE 291 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 292 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 225 TABLE 293 INDIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 294 INDIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 295 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 226 TABLE 296 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 227 TABLE 297 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 298 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 299 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 228 TABLE 300 AUSTRALIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 301 AUSTRALIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 302 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 229 TABLE 303 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 230 TABLE 304 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 305 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 306 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 231 TABLE 307 SOUTH KOREA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 308 SOUTH KOREA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 309 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 232 TABLE 310 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 233 TABLE 311 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 312 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 313 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 234 TABLE 314 REST OF ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 315 REST OF ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 316 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 235 TABLE 317 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 236 TABLE 318 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 236 TABLE 319 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 237 TABLE 320 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 321 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 238 TABLE 322 LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 323 LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 324 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 239 TABLE 325 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 239 TABLE 326 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240 TABLE 327 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 328 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 241 TABLE 329 BRAZIL: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 330 BRAZIL: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 331 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 242 TABLE 332 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 242 TABLE 333 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 334 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 335 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 244 TABLE 336 MEXICO: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 337 MEXICO: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 338 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 245 TABLE 339 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 245 TABLE 340 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 341 MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 246 TABLE 342 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 247 TABLE 343 REST OF LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 344 REST OF LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 345 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 248 TABLE 346 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 248 TABLE 347 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 248 TABLE 348 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 249 TABLE 349 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION) 249 TABLE 350 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 250 TABLE 351 MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 352 MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 353 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 251 TABLE 354 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 251 TABLE 355 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 356 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 252 TABLE 357 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 253 TABLE 358 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 253 TABLE 359 GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 360 GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 361 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 254 TABLE 362 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 254 TABLE 363 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 364 GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 255 TABLE 365 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 256 TABLE 366 KINGDOM OF SAUDI ARABIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 367 KINGDOM OF SAUDI ARABIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 368 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 257 TABLE 369 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 257 TABLE 370 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 258 TABLE 371 KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 372 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 259 TABLE 373 UAE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 374 UAE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 375 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 260 TABLE 376 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 260 TABLE 377 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 378 UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 261 TABLE 379 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 262 TABLE 380 REST OF GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 381 REST OF GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 382 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 263 TABLE 383 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 263 TABLE 384 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 385 REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 386 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 265 TABLE 387 REST OF MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 388 REST OF MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 389 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 266 TABLE 390 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 266 TABLE 391 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 392 REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 267 TABLE 393 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION) 268 TABLE 394 AFRICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 395 AFRICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 396 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION) 269 TABLE 397 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION) 269 TABLE 398 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270 TABLE 399 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION) 270 TABLE 400 STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022−2025 271 TABLE 401 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEGREE OF COMPETITION 274 TABLE 402 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: REGION FOOTPRINT 279 TABLE 403 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: MODEL TYPE & SERVICE FOOTPRINT 280 TABLE 404 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TUMOR TYPE FOOTPRINT 281 TABLE 405 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPLANTATION METHOD FOOTPRINT 282 TABLE 406 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 285 TABLE 407 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY MODEL TYPE & SERVICE AND REGION 286 TABLE 408 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEALS, JANUARY 2022− OCTOBER 2025 289 TABLE 409 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: EXPANSIONS, JANUARY 2022− OCTOBER 2025 290 TABLE 410 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 291 TABLE 411 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 292 TABLE 412 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–OCTOBER 2025 294 TABLE 413 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–OCTOBER 2025 295 TABLE 414 THE JACKSON LABORATORY: COMPANY OVERVIEW 297 TABLE 415 THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED 298 TABLE 416 THE JACKSON LABORATORY: DEALS, JANUARY 2022–OCTOBER 2025 299 TABLE 417 THE JACKSON LABORATORY: EXPANSIONS, JANUARY 2022–OCTOBER 2025 300 TABLE 418 INOTIV: COMPANY OVERVIEW 302 TABLE 419 INOTIV: PRODUCTS/SERVICES OFFERED 303 TABLE 420 INOTIV: EXPANSIONS, JANUARY 2022–OCTOBER 2025 305 TABLE 421 JSR CORPORATION: COMPANY OVERVIEW 307 TABLE 422 JSR CORPORATION: PRODUCTS/SERVICES OFFERED 308 TABLE 423 JSR CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 309 TABLE 424 JSR CORPORATION: EXPANSIONS, JANUARY 2022–OCTOBER 2025 310 TABLE 425 GENOWAY: COMPANY OVERVIEW 311 TABLE 426 GENOWAY: PRODUCTS/SERVICES OFFERED 312 TABLE 427 WUXI APPTEC + WUXI BIOLOGICS: COMPANY OVERVIEW 314 TABLE 428 WUXI APPTEC + WUXI BIOLOGICS: PRODUCTS/SERVICES OFFERED 315 TABLE 429 WUXI APPTEC + WUXI BIOLOGICS: DEALS, JANUARY 2022–OCTOBER 2025 316 TABLE 430 WUXI APPTEC + WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–OCTOBER 2025 318 TABLE 431 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 319 TABLE 432 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCTS/SERVICES OFFERED 320 TABLE 433 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCT/SERVICE UPGRADES, JANUARY 2022–OCTOBER 2025 321 TABLE 434 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: EXPANSIONS, JANUARY 2022–OCTOBER 2025 321 TABLE 435 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW 323 TABLE 436 TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 323 TABLE 437 TACONIC BIOSCIENCES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2022–OCTOBER 2025 324 TABLE 438 TACONIC BIOSCIENCES, INC.: DEALS, JANUARY 2022–OCTOBER 2025 325 TABLE 439 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2022–OCTOBER 2025 325 TABLE 440 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): COMPANY OVERVIEW 326 TABLE 441 ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): PRODUCTS/SERVICES OFFERED 326 TABLE 442 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW 328 TABLE 443 CHAMPIONS ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED 329 TABLE 444 CHAMPIONS ONCOLOGY, INC.: DEALS, JANUARY 2022–OCTOBER 2025 329 TABLE 445 PHARMARON: COMPANY OVERVIEW 330 TABLE 446 PHARMARON: PRODUCTS/SERVICES OFFERED 331 TABLE 447 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW 333 TABLE 448 SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES OFFERED 334 TABLE 449 LABCORP: COMPANY OVERVIEW 335 TABLE 450 LABCORP: PRODUCTS/SERVICES OFFERED 336 TABLE 451 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 337 TABLE 452 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 338 TABLE 453 VITALSTAR BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 339 TABLE 454 VITALSTAR BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED 339 TABLE 455 CREATIVE ANIMODEL: COMPANY OVERVIEW 340 TABLE 456 JOINN LABORATORIES (CHINA) CO., LTD.: COMPANY OVERVIEW 341 TABLE 457 CREATIVE BIOLABS: COMPANY OVERVIEW 342 TABLE 458 ARAGEN LIFE SCIENCES LTD.: BUSINESS OVERVIEW 343 TABLE 459 PHARMATEST: BUSINESS OVERVIEW 344 TABLE 460 LIDE SHANGHAI BIOTECH CO., LTD.: COMPANY OVERVIEW 345 TABLE 461 CERTIS ONCOLOGY SOLUTIONS: COMPANY OVERVIEW 345 TABLE 462 INNOSER: COMPANY OVERVIEW 346 TABLE 463 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW 346 TABLE 464 IVRS AB: COMPANY OVERVIEW 347 TABLE 465 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: IMPACT ANALYSIS 358 TABLE 466 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: RISK ANALYSIS 358 FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION & REGIONAL SCOPE 36 FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: YEARS CONSIDERED 37 FIGURE 3 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2025 VS. 2030 (USD MILLION) 40 FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2025 VS. 2030 (USD MILLION) 41 FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2025 VS. 2030 (USD MILLION) 41 FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 42 FIGURE 7 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 43 FIGURE 8 GROWING DEMAND FOR IMMUNO-ONCOLOGY AND COMPLEX BIOLOGICS TO DRIVE MARKET 45 FIGURE 9 US AND PDX MODELS COMMANDED LARGEST MARKET SHARE IN 2024 46 FIGURE 10 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 47 FIGURE 11 SUBCUTANEOUS IMPLANTATION TO DOMINATE MARKET DURING FORECAST PERIOD 47 FIGURE 12 MODEL CREATION & EXPANSION ACCOUNTED FOR LARGEST MARKET MARKET SHARE IN 2024 48 FIGURE 13 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49 FIGURE 14 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: PORTER’S FIVE FORCES 56 FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ECOSYSTEM ANALYSIS 58 FIGURE 16 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: VALUE CHAIN ANALYSIS 59 FIGURE 17 AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER, 2022–2024 (USD) 61 FIGURE 18 AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024 (USD) 63 FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 64 FIGURE 20 PATENT APPLICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, JANUARY 2014–DECEMBER 2024 65 FIGURE 21 NUMBER OF DEALS AND FUNDING IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2025 (USD MILLION) 76 FIGURE 22 TOP USE CASES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET 80 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON DECISION-MAKING FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS 94 FIGURE 24 BUYING EVALUATION CRITERIA FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS 95 FIGURE 25 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SNAPSHOT 184 FIGURE 26 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SNAPSHOT 216 FIGURE 27 REVENUE ANALYSIS FOR KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2024 (USD MILLION) 273 FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 274 FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2024, 277 FIGURE 30 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY FOOTPRINT 278 FIGURE 31 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 284 FIGURE 32 EV/EBITDA OF KEY VENDORS 286 FIGURE 33 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 287 FIGURE 34 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 288 FIGURE 35 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 292 FIGURE 38 JSR CORPORATION: COMPANY SNAPSHOT 308 FIGURE 39 GENOWAY: COMPANY SNAPSHOT 311 FIGURE 40 WUXI APPTEC + WUXI BIOLOGICS: COMPANY SNAPSHOT 315 FIGURE 41 BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT 320 FIGURE 42 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT 328 FIGURE 43 PHARMARON: COMPANY SNAPSHOT 331 FIGURE 44 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT 333 FIGURE 45 LABCORP: COMPANY SNAPSHOT 336 FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 338 FIGURE 47 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: RESEARCH DESIGN 348 FIGURE 48 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 350 FIGURE 49 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 350 FIGURE 50 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 351 FIGURE 51 PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ILLUSTRATIVE REVENUE ANALYSIS OF CHARLES RIVER LABORATORIES (2024) 352 FIGURE 52 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 353 FIGURE 53 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 353 FIGURE 54 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: CAGR PROJECTIONS 355 FIGURE 55 PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: DATA TRIANGULATION METHODOLOGY 356

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們